Literature DB >> 16186533

Diagnostic evaluation of patients with a brain mass as the presenting manifestation of cancer.

A N Mavrakis1, E F Halpern, F G Barker, R G Gonzalez, J W Henson.   

Abstract

BACKGROUND: Patients with a newly detected brain mass and no history of cancer often undergo extensive diagnostic testing in search of a systemic primary neoplasm prior to selection of a biopsy site, potentially leading to unnecessary expense and delay. We sought patterns in the evaluation of these patients to allow rapid selection of a biopsy site.
METHODS: We compared the diagnostic evaluation of 176 patients with newly detected brain masses who were ultimately determined to have a metastatic or primary lesion.
RESULTS: In 88 patients presenting with brain metastasis, lung cancer was markedly overrepresented as a primary tumor, occurring in 82% of patients. Brain MRI and chest CT together identified the site for diagnostic biopsy in all except for two of the 176 patients. One-half of the patients with metastasis had brain biopsy as the primary diagnostic procedure, with 80% undergoing a craniotomy rather than needle biopsy. The initial management decision in the majority of metastasis patients was whether to perform a craniotomy for resection of tumor. Whereas patients with single and cerebellar lesions were most likely to undergo craniotomy, the extent of systemic disease did not affect the decision to recommend a neurosurgical procedure. The average time to biopsy for patients with metastatic and primary tumors was 4.7 days and 6.0 days. In this retrospective population, we estimated that evaluation with brain MRI and chest CT, followed by an early neurosurgical decision, could reduce the time to diagnosis by at least 10%.
CONCLUSIONS: Chest CT and brain MRI, if used together as initial diagnostic studies, would have identified a biopsy site in 97% of patients with a newly detected brain mass.

Entities:  

Mesh:

Year:  2005        PMID: 16186533     DOI: 10.1212/01.wnl.0000176059.21455.76

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

1.  Rapidly progressive coma, hydrocephalus and leukoencephalopathy as presenting features of leptomeningeal metastases.

Authors:  J M F Niermeijer; M Somers; W Spliet; J C Reijneveld; G J Biessels
Journal:  J Neurol       Date:  2007-11-15       Impact factor: 4.849

2.  Epidemiology of brain metastases.

Authors:  Lakshmi Nayak; Eudocia Quant Lee; Patrick Y Wen
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

3.  An unusual cause of a fall: an unusual presentation of lung carcinoma.

Authors:  Xin-Ying Kowa; Catherine Hyams; Mark Farrugia; Sara Lightowlers
Journal:  BMJ Case Rep       Date:  2014-05-07

4.  Small cell carcinoma of the brain without extracranial involvement by serial CT, MRI and PET.

Authors:  Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2010-01-28

Review 5.  Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment.

Authors:  Gagandeep Singh; Jeremy H Rees; Josemir W Sander
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-04       Impact factor: 10.154

Review 6.  Operative and peri-operative considerations in the management of brain metastasis.

Authors:  Eric W Sankey; Vadim Tsvankin; Matthew M Grabowski; Gautam Nayar; Kristen A Batich; Aida Risman; Cosette D Champion; April K S Salama; C Rory Goodwin; Peter E Fecci
Journal:  Cancer Med       Date:  2019-09-30       Impact factor: 4.452

7.  Occult very small lung carcinoma with a solitary brain metastasis that is clinically diagnosed as cavernous hemangioma: a case report.

Authors:  Tadashi Terada
Journal:  Cases J       Date:  2009-08-19

8.  Neuropathology of brain metastases.

Authors:  Melike Pekmezci; Arie Perry
Journal:  Surg Neurol Int       Date:  2013-05-02

9.  Pulmonary neuroendocrine carcinoma mimicking neurocysticercosis: a case report.

Authors:  John C Lam; Stephen R Robinson; Andrew Schell; Stephen Vaughan
Journal:  J Med Case Rep       Date:  2016-06-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.